Format

Send to

Choose Destination
Int J Mol Sci. 2017 Feb 18;18(2). pii: E445. doi: 10.3390/ijms18020445.

PET Imaging for Initial Staging and Therapy Assessment in Multiple Myeloma Patients.

Author information

1
Nantes-Angers Cancer Research Center (CRCNA), University of Nantes, Inserm UMR 1232, 8 quai Moncousu, 44007 Nantes, France. clement.bailly@chu-nantes.fr.
2
Department of Nuclear Medicine, CHU de Nantes, 1 place Alexis Ricordeau, 44093 Nantes, France. clement.bailly@chu-nantes.fr.
3
Department of Nuclear Medicine, CHU de Nantes, 1 place Alexis Ricordeau, 44093 Nantes, France. rodolpheleforestier@hotmail.fr.
4
Department of Nuclear Medicine, CHU de Nantes, 1 place Alexis Ricordeau, 44093 Nantes, France. bastien.jamet@chu-nantes.fr.
5
Nantes-Angers Cancer Research Center (CRCNA), University of Nantes, Inserm UMR 1232, 8 quai Moncousu, 44007 Nantes, France. thomas.carlier@chu-nantes.fr.
6
Department of Nuclear Medicine, CHU de Nantes, 1 place Alexis Ricordeau, 44093 Nantes, France. thomas.carlier@chu-nantes.fr.
7
Nantes-Angers Cancer Research Center (CRCNA), University of Nantes, Inserm UMR 1232, 8 quai Moncousu, 44007 Nantes, France. mickael.bourgeois@nantes.inserm.fr.
8
Department of Nuclear Medicine, CHU de Nantes, 1 place Alexis Ricordeau, 44093 Nantes, France. mickael.bourgeois@nantes.inserm.fr.
9
Nantes-Angers Cancer Research Center (CRCNA), University of Nantes, Inserm UMR 1232, 8 quai Moncousu, 44007 Nantes, France. francois.guerard@univ-nantes.fr.
10
Department of Nuclear Medicine, CHU de Nantes, 1 place Alexis Ricordeau, 44093 Nantes, France. cyrille.touzeau@chu-nantes.fr.
11
Department of Nuclear Medicine, CHU de Nantes, 1 place Alexis Ricordeau, 44093 Nantes, France. philippe.moreau@chu-nantes.fr.
12
Nantes-Angers Cancer Research Center (CRCNA), University of Nantes, Inserm UMR 1232, 8 quai Moncousu, 44007 Nantes, France. michel.cherel@univ-nantes.fr.
13
Department of Nuclear Medicine, ICO-René Gauducheau, Boulevard Jacques Monod, 44805 Saint-Herblain, France. michel.cherel@univ-nantes.fr.
14
Nantes-Angers Cancer Research Center (CRCNA), University of Nantes, Inserm UMR 1232, 8 quai Moncousu, 44007 Nantes, France. francoise.bodere@chu-nantes.fr.
15
Department of Nuclear Medicine, CHU de Nantes, 1 place Alexis Ricordeau, 44093 Nantes, France. francoise.bodere@chu-nantes.fr.
16
Department of Nuclear Medicine, ICO-René Gauducheau, Boulevard Jacques Monod, 44805 Saint-Herblain, France. francoise.bodere@chu-nantes.fr.
17
Nantes-Angers Cancer Research Center (CRCNA), University of Nantes, Inserm UMR 1232, 8 quai Moncousu, 44007 Nantes, France. caroline.milin@chu-nantes.fr.
18
Department of Nuclear Medicine, CHU de Nantes, 1 place Alexis Ricordeau, 44093 Nantes, France. caroline.milin@chu-nantes.fr.

Abstract

Multiple myeloma (MM) is a hematological neoplasm characterized by the clonal proliferation of malignant plasma cells in the bone marrow. MM results in diffuse or focal bone infiltration and extramedullary lesions. Over the past two decades, advances have been made with regard to the diagnosis, staging, treatment, and imaging of MM. Computed tomography (CT) and magnetic resonance imaging (MRI) are currently recommended as the most effective imaging modalities at diagnostic. Yet, recent data from the literature suggest that positron emission tomography combined with computed tomography (PET/CT) using 18F-deoxyglucose (FDG) is a promising technique for initial staging and therapeutic monitoring in this pathology. This paper reviews the recent advances as well as the potential place of a more specific radiopharmaceutical in MM.

KEYWORDS:

PET/CT; multiple myeloma; solitary plasmacytoma; therapeutic evaluation

PMID:
28218709
PMCID:
PMC5343979
DOI:
10.3390/ijms18020445
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Multidisciplinary Digital Publishing Institute (MDPI) Icon for PubMed Central
Loading ...
Support Center